



WHERE TECHNOLOGY COMES TO **LIFE**

Q2 2026



Forward Looking Statement

This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the "Company" or "Pluri"), to the extent such statements do not relate to historical or current facts. For example, the Company is using forward-looking statements when it discusses the potential benefits of its solutions and the solutions of its subsidiaries and joint venture; its ability to create a collaborative network of ventures and partnerships; the ability of its technological platform; its ability to retain majority share ownership in every venture it creates; its ability to grow stronger and drive continuous innovation and success; and potential market size and growth for its solutions. Forward-looking statements are based on management's current expectations, estimates, projections, and assumptions about future events, and are subject to several factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions about the Company, which are difficult to predict, including projections of the Company's future financial results, its anticipated growth strategies, and anticipated trends in its business and in the market generally. Therefore, actual future results, performance and trends may differ materially from these forward-looking statements due to a variety of factors, including, without limitation: changes in technology and market requirements; the Company may encounter delays or obstacles in launching and/or successfully completing its proposed plans, including research and development; its products may not be approved by regulatory agencies, their technology may not be validated as they progress further and their methods may not be accepted; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real world settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of the Company or its joint ventures to differ materially from those contemplated in such forward-looking statements. The factors listed above are not exclusive, and further information is contained in the Company's Annual Report on Form 10-K and other reports on file with the U.S. Securities and Exchange Commission. All forward-looking statements speak only as of the date of this presentation. Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance, or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities of the Company. The information to be presented is not intended to replace the need to review the Company's formal filings with the U.S Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K and any subsequent filings, prior to making any investment in the Company's securities. In case of any inconsistencies between the information provided in this presentation and the Company's regulatory filings, the latter will prevail. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission and available on the SEC's website, www.sec.gov.

Pluri Venture Creation



Company

- Nasdaq (PLUR), TASE (PLUR.Ta)
- Cash & Deposits: ~\$14 million (as of December 31, 2025)
- Chairman- **Alejandro Weinstein**
- Based In Israel With **Global Presence** (USA and Europe)
- Rich IP Portfolio With **>200 Patents** Globally
- GMP Compliance Declaration
- **Two Decades Of Experience** In Cell Processing And Mass Scale Technology Development



Sectors



Regenerative
Medicine and
wellness



Cultivated Meat
Cell-Based
Agriculture



Partners



EUROPEAN MEDICINES AGENCY



Eight Billion Lives. **One Planet.** **Zero Time to Waste.**



Aging and Health



Climate Change



Food Security



Sustainability

**A growing, aging world urgently needs
scalable, sustainable solutions**

Single Platform, Multiple Opportunities

plurihealth Human health and Longevity


Placental cell therapy

Injectable placental cell-based therapy designed to reduce inflammation and promote tissue healing


- ◆ **Longevity**
- ◆ **Immunotherapy**
- ◆ **Osteoarthritis** - Full funding for PROTO consortium


Medical aesthetics

Breakthrough cellular technology for the next generation of skin therapies and regenerative medicine

- ◆  - 100% ownership


plurifood

Cultivated coffee 100% ownership 

Cultivated cacao 79% ownership 

Cell-based agriculture

- Funded POC with ICL
- Funded POC with global Agriculture Corp.

Cultivated meat 69% ownership
at a value of \$62 million 

Knowhow
and expertise

Validated
technology
and robust IP

Deep market
understanding and
strong partnerships

Infrastructure
and corporate
services

GMP Compliance
Declaration

Pluri Technological Platform

Cell-based innovations, powered by validated technology

Innovative

- **Patented 3D cell expansion**
High-quality cells produced in large quantities
- **Versatile cell source and types**
Compatible with human, animal, and plant cells
- **Modular production system**
Reduces costs and minimizes ecological impact

Validated

- **Automated, scalable process**
Efficient and fully controlled
- **GMP Compliance Declaration**
Ensures quality and compliance with standards
- **Consistent batch production**
Proven reliability from batch to batch



Pluri Technological Platform


Bio-Farming: Industrial Scale Production

Advantages

- **Low production costs**
Significantly lower production costs compared to traditional methods
- **Maintaining high quality**
Critical advantage in emerging industries such as cultured meat, coffee, cacao, etc.
- **Intelligent control system**
Reduces the need for personal intervention, ensures consistency and quality



PluriMatrix™


A background image showing a microscopic view of several cells, likely fibroblasts or epithelial cells, with visible nuclei and cytoplasm. The cells are arranged in a cluster, and the image is overlaid with a semi-transparent light blue rectangle on the left side where the text is located.

Health and Wellbeing: Supporting Longevity and the Aging Process

Longevity and the Aging Process: Physical Deterioration Over Time

The World Health Organization ([WHO](#)) has declared its focus on aging with the goals of **transformation for healthy ageing and long-term care**:
Integrate prevention, reshape care, foster enabling environments and address ageism – highlighting local solutions that can drive change across systems and settings.

Pluri is offering health and wellbeing solutions, supporting regeneration, rehabilitation and natural healing processes.



Neuronal degeneration

Muscle wasting

Ischemia


Inflammation

Hematopoietic system
weakening

Cancerous Cells

Senescent Cells

One Platform. Multiple Products.



Vascular

- Critical Limb Ischemia (Phase III)
Reduction in events of death and amputations at 1-year*
(34% vs 15% placebo)

Orthopedics/ inflammatory


- Muscle & tissue regeneration (Phase III)
improvement in muscle strength & muscle volume
- Knee OA (Phase I)

Hematological deficiencies

- Poor graft function (Phase I)
- Acute radiation syndrome (Animal rule pathway)
Improves survival (18% vs 29% **), improves bone marrow cell count, decrease in blood transfusions (platelets: 5.1 at baseline vs 0.55 at month 12, red blood cell: 2.91 at baseline vs 0 at month 12)

Professional skin care line

Regenerative skin support, Antioxidant protection, Anti-inflammatory action, Wound-healing support, Collagen-boosting
(*"Dermatologically tested"*, *"Clinically tested"*, *"Safe for skin"*, *"Kind to skin"*, *"Dermatologist Approved"*)



* Subgroup analysis of patients with baseline HbA1c levels below 6.5%

** annual mortality rate in PLX treated patient vs Center for International Blood and Marrow Transplant Research (CIBMTR) registry data

Stem Cell Use Authorization in the US



Premium Aesthetics Solutions

Florida law ([SB 1768 / HB 1617](#)) passed on July, 2025

Authorizes the use of cell therapies, subject to **highest standards** of manufacturing and **ethically-sourced** cells. This includes the therapeutic fields of **orthopedics, wound care and Pain management.**

Revolutionizing Beauty and Wellness Through Cell Science



Market Opportunity

The global aesthetics and wellness industry exceeds \$200B, driven by demand for evidence-based, biotech-powered, and clean solutions



Science-Driven Innovation

CellaV develops bioactive ingredients and finished products rich in exosomes, cytokines, and growth factors - designed to rejuvenate, repair, and elevate skin vitality



From Therapy to Lifestyle

Cellav transforms decades of cell-science expertise into next-generation solutions for aesthetics, health, and well-being



Partnership & Growth

Cellav expects to collaborate with brands, clinics, and distributors offering ingredients, finished products and co-development - delivering science-based, ready-to-market solutions



Ingredients:

- Human Placental cells Conditioned Media
- Coffea Arabica Callus Extracellular Vesicles
- Human Placental Stromal Cell Exosomes

Foodtech

Partnership that Becomes Independence: a Proven Path to Value Creation

**Pluri holds majority ownership in all
companies in which it is a partner**

Growing the Future of Food with Cultivated Meat

Ever After Foods leverages Pluri's cell expansion technology to produce mass scale, cost-effective food products in an efficient and sustainable manner, aiming to solve the industry's scalability challenges



Environmental

- Less land and water are required
- Fewer greenhouse gases
- Less agriculture-related pollution



Ethical

- Adheres to ethical animal welfare standards



Consumer

- Natural flavor modification
- Safe modification for healthier food and raw materials

Ever After Foods Milestones



Jan.
2022



Collaboration between Pluri and Tnuva announced

 **~84.2% ownership**

Granted exclusive global royalty-bearing license to use its IP and expertise

 **~15.8% ownership**

Invested \$7.5 million according to a **\$40 million pre-money valuation**

Mar.
2023



Launch of a **scalable platform** for **cost effective production** of cultivated meat products

Jun.
2024



\$10 million investment round led by **leading global corporates**

- License extended to include cultivated fish
- **Post investment Pluri holds 69%**

Feb.
2025



Ever After Foods and **Bühler collaborate to scale cultivated meat production** and distribution



2026



Expected completion of manufacturing system development, initiation of regulatory processes, and receipt of initial regulatory approvals in selected markets

Reimagining Coffee & Cacao Without Ecological Cost

kokomodo
Cultivating Cocoa's Future

 **coffeesai**



Unstable supply

Global production expected to decrease due to climate change, diseases affecting trees and suitable land for growing Coffee or Cacao



Complex supply chain

High CO₂ emission and large amount of water are required for production; High carbon footprint resulting from transportation



Inconsistent quality

Heavy metals, pesticides, and inconsistencies in the production process can affect the quality of the product



Rising prices

U.S. coffee import prices have risen by over 65%. Prices changed from \$390 cents per kg to \$624 and back to \$419 cents per kg (2009-2023)

In 2024, cocoa prices soared by over 170%, reaching a record high of over \$11,000 per ton. The International Cocoa Organization forecasts a shortage which could lead to further price increases.



Milestones



**Jan.
2024**



Internal POC
(funded by Pluri)

**May
2024**



Company creation,
CEO and team
recruitment

**Sep.
2024**



Product
prototype

**H2
2025**



POC deals with
global partners

2026



Completion of product POC with
the Japanese partner

Progress to Regulatory
submissions in the U.S. and Israel



**Feb.
2024**



Company founded by Plantae
Bioscience, The Kitchen
(a Strauss Group company),
and Tal Govrin.
An investment of ~2.5 million NIS
was made for initial feasibility

**May
2025**



Completion of acquisition by Pluri



~79% ownership

**H2
2025**



POC deals with
global partners

2026



Completion of development
processes to scale up production
volumes

Completion of all main elements
for Regulatory submissions in the
U.S. and Israel

Our Collaborative Network of Partnerships

Regulatory



EUROPEAN MEDICINES AGENCY



Scientific Collaborations and Partnering



Funding



Our Team



Yaky Yanay
CEO & President



Liat Zalts
Chief Financial Officer



Lior Raviv
Chief Technology Officer



Dr. Michal Sheleg, PhD
VP Clinical Development



Nimrod Bar Zvi
Chief Commercial Officer



Dr. Arthur Machlenkin, PhD
Chief Scientific Officer



Nofar Gleich-Dabach
VP Human Resources



Orly Amiran
Chief Quality Officer



Efrat Kaduri
Chief BD Officer - Pharma



Ori Shalem
VP Operations & Manufacturing

THANK YOU.

Our cell-based innovations are aimed at transforming industries with a goal to create a more sustainable, healthier world. From the food we eat to the medicine we consume, we are building solutions that can potentially serve humanity, one breakthrough at a time.



For further info: investor.relations@pluri-biotech.com